#152695

Anti-Melanoma [LHM3]

Please Enter Your Email ID
Email ID

Cat. #152695

Anti-Melanoma [LHM3]

Cat. #: 152695

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Melanoma

Class: Monoclonal

Application: IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Nick Tidman

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Melanoma [LHM3]
  • Cancers detailed: Broadly Applicable
  • Research fields: Cancer;Cell biology
  • Clone: LHM3
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 120 kDa
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; IP ; WB
  • Description: LHM3 can be used in a diagnostic panel for immunopathology of malignant melanoma. Potential candidate for immunoimaging and immunotherapy of disseminated melanoma.
  • Immunogen: A 375P cell extract
  • Isotype: IgG1 kappa

Target Details

  • Target: Melanoma
  • Molecular weight: 120 kDa
  • Target background: LHM3 can be used in a diagnostic panel for immunopathology of malignant melanoma. Potential candidate for immunoimaging and immunotherapy of disseminated melanoma.

Applications

  • Application: IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Kupsch et al. 1995. Melanoma Res. 5(6):403-11. PMID: 8589614.
  • Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens.